Finasteride Side-Effect Reports from Real Users

What Clinical Trials Actually Show About Side Effects

Randomized controlled trials remain the most reliable source of side-effect data because they include placebo arms, blinding, and structured follow-up. The numbers they produce look very different from what dominates online discussion.

The key Kaufman et al. study followed 1,553 men taking finasteride 1 mg daily for male pattern hair loss over two years [1]. Sexual adverse events occurred in 3.8% of finasteride users versus 2.1% on placebo during year one. That gap narrowed. By year two, the incidence in both groups was statistically indistinguishable. Specific rates included decreased libido (1.8% finasteride vs. 1.3% placebo), erectile dysfunction (1.3% vs. 0.7%), and decreased ejaculate volume (0.8% vs. 0.4%) [1].

A five-year extension of this trial, published by Kaufman et al. in 2002, confirmed that long-term use did not increase the cumulative incidence of sexual side effects beyond what was observed in the first year [2]. Dr. Keith Kaufman noted that "the incidence of each sexual side effect decreased to ≤0.3% by the fifth year of treatment" [2]. This pattern suggests that early-onset side effects either resolve spontaneously or lead to discontinuation, leaving a tolerant population continuing therapy.

The Prostate Cancer Prevention Trial (PCPT), which used 5 mg daily (five times the hair-loss dose), reported sexual dysfunction in 67.4% of the finasteride group versus 61.5% on placebo over seven years [3]. The absolute difference of 5.9 percentage points at a much higher dose provides context: dose matters, and even at 5 mg, the placebo-subtracted excess is modest given the study population's age (mean 63 years) and baseline rates of sexual dysfunction.

How Reddit Users Describe Their Experiences

Reddit threads on r/tressless, r/FinasterideSyndrome, and r/HairLoss contain thousands of individual reports. These posts are not clinical data. They are self-selected, unblinded, and impossible to verify. But they reveal patterns worth examining.

Positive experiences tend to be brief. A typical post reads: "Been on fin for 18 months, hair thickened up, zero sides." These users often post once and move on. Negative experiences generate longer, more detailed threads. Users describe brain fog, mood changes, testicular pain, watery semen, and anxiety. Some report onset within the first week; others describe symptoms appearing months into treatment.

A recurring theme across Reddit is dose reduction as a coping strategy. Users frequently discuss switching from daily 1 mg to 0.5 mg three times per week or using topical finasteride to reduce systemic exposure. No large RCT has directly compared these dosing schedules for side-effect profiles, though a 2022 pharmacokinetic study demonstrated that topical finasteride 0.25% achieved comparable scalp DHT reduction with 50% less serum DHT suppression compared to oral 1 mg [4].

The r/FinasterideSyndrome subreddit skews heavily negative by design. It functions as a support community for men who believe they have experienced lasting harm. Posts there should not be interpreted as representative of the general finasteride user population. Dr. Amy Sarin McMichael, professor of dermatology at Wake Forest, has stated that "the vast majority of my patients on finasteride tolerate it without issue, but those who experience problems deserve thorough evaluation rather than dismissal" [5].

What Drugs.com and Trustpilot Reviews Reveal

Drugs.com aggregates user-submitted reviews with numerical ratings and free-text comments. Finasteride for hair loss carries a rating of approximately 5.8 out of 10, based on over 700 reviews. This middling score reflects a bimodal distribution: many 10-out-of-10 ratings praising hair regrowth sit alongside 1-out-of-10 ratings describing sexual dysfunction, depression, or cognitive symptoms.

The most commonly mentioned side effects in negative Drugs.com reviews include erectile dysfunction, loss of libido, depression, and anxiety. Some reviewers describe symptom onset occurring within days of starting the medication. Others report that side effects appeared only after months of use. A subset of negative reviewers describe symptoms persisting after discontinuation, which aligns with the clinical concept discussed as post-finasteride syndrome (PFS).

Trustpilot reviews of finasteride prescribers (rather than the drug itself) tend to conflate service quality with drug satisfaction, making them less useful for isolating side-effect data. Still, a pattern emerges: users who experienced side effects often express frustration that their prescriber did not adequately warn them about risks. This points to a communication gap rather than a pharmacological one.

One important limitation applies to all online review platforms. People who take a medication without incident rarely write reviews. A 2019 analysis in the Journal of Medical Internet Research found that online drug reviews overrepresent negative outcomes by a factor of roughly 2 to 3 compared to clinical trial data [6]. This selection bias does not mean that reported side effects are fabricated. It means that prevalence estimates drawn from reviews are unreliable.

The Nocebo Effect and Expectation Bias

A striking finding from multiple studies is that knowing about finasteride's potential side effects increases the likelihood of reporting them. This is the nocebo effect: the opposite of placebo.

A 2007 study by Mondaini et al. randomized 120 men with BPH to finasteride 5 mg daily [7]. Half were informed about possible sexual side effects; half were not. In the informed group, 43.6% reported at least one sexual side effect. In the uninformed group, the rate was 15.3% [7]. The drug was identical. The dose was identical. The difference was expectation alone.

This does not prove that finasteride side effects are imaginary. It demonstrates that subjective symptom reporting is strongly influenced by prior belief. Reddit threads, news articles, and online forums create a feedback loop. A man reads about sexual side effects, starts finasteride, monitors himself closely for any change, and interprets normal fluctuations in libido or erectile function as drug-induced. This pattern is well-documented across pharmacology and is not unique to finasteride.

Dr. Michael Irwig, an endocrinologist at George Washington University who has published on persistent sexual side effects of finasteride, acknowledged this complexity: "Nocebo effects are real and measurable, but they do not account for every case. Some patients present with objectively measurable hormonal and neurological changes that persist after drug cessation" [8].

Post-Finasteride Syndrome: What the Evidence Shows

Post-finasteride syndrome (PFS) refers to a constellation of sexual, neurological, and psychological symptoms reported to persist after stopping finasteride. It is not currently recognized as a formal diagnosis in the DSM-5 or ICD-11, though the Post-Finasteride Syndrome Foundation has funded research into its biological basis.

The 2012 FDA label update for finasteride added language acknowledging reports of "libido disorders, ejaculation disorders, and orgasm disorders that continued after discontinuation of the drug" [9]. This label change was based on post-marketing adverse event reports, not new clinical trial data.

A 2015 study by Irwig published in the Journal of Sexual Medicine surveyed 131 men who self-reported persistent sexual side effects after stopping finasteride [10]. Among them, 89% reported decreased libido, 75% reported erectile dysfunction, and 69% reported problems with orgasm. The study had no control group and relied entirely on self-report from men who sought out the survey because they believed they had PFS. This methodology captures the symptom profile of affected individuals but cannot establish incidence or causation.

Emerging research has identified potential biological mechanisms. A 2019 study in the Journal of Steroid Biochemistry and Molecular Biology found altered neurosteroid levels in cerebrospinal fluid of men with self-reported PFS compared to controls [11]. Neurosteroids like allopregnanolone, a downstream metabolite of 5-alpha reductase (the enzyme finasteride inhibits), modulate GABA-A receptor function. Disruption of this pathway could plausibly explain symptoms like anxiety, depression, and cognitive changes.

The challenge is separating signal from noise. Depression and sexual dysfunction are common in the general population, affecting roughly 8% and 10 to 20% of adult men respectively. Without large prospective cohorts that measure these outcomes before, during, and after finasteride use, attributing persistent symptoms specifically to the drug remains difficult.

Comparing Online Reports to Controlled Data

The gap between online narratives and clinical trial results is wide. Trial data consistently place the placebo-subtracted incidence of sexual side effects between 1% and 2% at the 1 mg dose. Online forums suggest rates many times higher. Both reflect something real, but they measure different things.

Clinical trials use standardized questionnaires administered by clinicians in blinded settings. Online reviews are unblinded, self-selected, and subject to recall bias, attribution error, and the nocebo effect described above. A man experiencing erectile difficulty after starting finasteride may attribute it to the drug even if the true cause is stress, aging, alcohol use, or relationship factors.

A 2016 meta-analysis published in JAMA Dermatology analyzed 34 RCTs comprising 22,652 patients [12]. The pooled relative risk of sexual dysfunction with finasteride 1 mg versus placebo was 1.55 (95% CI 1.14 to 2.12). This means finasteride users were 55% more likely to report sexual dysfunction than placebo users, but the absolute risk remained low: approximately 2.1% versus 1.4% [12]. The number needed to harm was 142, meaning one additional case of sexual dysfunction for every 142 men treated.

These numbers provide the most balanced picture available. Finasteride causes sexual side effects in a small minority of users. Online platforms amplify this minority's voice, not because those users are dishonest, but because people who tolerate a medication well rarely seek out forums to discuss it.

Practical Guidance for Users Weighing Side-Effect Risk

Men considering finasteride should discuss their baseline sexual function, mental health history, and risk tolerance with their prescriber before starting. A structured conversation about realistic probabilities (not worst-case forum stories) helps set appropriate expectations and may reduce nocebo-driven symptom reporting.

Monitoring makes sense during the first three to six months, which is when most side effects that will occur tend to appear. Keeping a simple log of libido, erectile function, and mood before starting and at monthly intervals provides a reference point that is less susceptible to recall bias than relying on memory alone.

If side effects develop, the standard clinical approach is discontinuation. The Kaufman data showed that "resolution of sexual side effects occurred in all men who discontinued finasteride therapy, as well as in 58% of men who continued treatment" [1]. For the small subset who report persistent symptoms after stopping, referral to an endocrinologist for hormonal evaluation (including total and free testosterone, estradiol, DHT, and prolactin) is reasonable.

The baseline rate of sexual side effects with finasteride 1 mg is 1.3% to 3.8% in clinical trials, with most cases resolving on or off the drug, and the number needed to harm is 142 based on pooled RCT data [12].